{"id":76075,"date":"2020-10-29T01:08:48","date_gmt":"2020-10-29T05:08:48","guid":{"rendered":"https:\/\/www.hedgeco.net\/news\/?p=76075"},"modified":"2020-10-29T01:18:59","modified_gmt":"2020-10-29T05:18:59","slug":"gileads-revenue-rises-17-driven-by-sales-of-coronavirus-treatment-remdesivir","status":"publish","type":"post","link":"https:\/\/hedgeco.net\/news\/10\/2020\/gileads-revenue-rises-17-driven-by-sales-of-coronavirus-treatment-remdesivir.html","title":{"rendered":"Gilead\u2019s revenue rises 17% driven by sales of coronavirus treatment remdesivir"},"content":{"rendered":"\n<p>(CNBC) <a href=\"https:\/\/www.cnbc.com\/quotes\/?symbol=GILD\">Gilead<\/a> <a href=\"https:\/\/www.cnbc.com\/quotes\/?symbol=GILD\">Sciences<\/a> reported stronger-than-expected third-quarter earnings on Wednesday as sales of its <a href=\"https:\/\/www.cnbc.com\/coronavirus\/\">coronavirus<\/a> treatment remdesivir touted by President <a href=\"https:\/\/www.cnbc.com\/donald-trump\/\">Donald Trump<\/a> drove revenue up by 17% from last year. Gilead\u2019s antiviral drug remdesivir, selling under the brand name Veklury, last week became the first and only treatment <a href=\"https:\/\/www.cnbc.com\/2020\/10\/22\/fda-approves-gileads-remdesivir-as-coronavirus-treatment.html\">granted full approval<\/a> by the U.S. Food and Drug Administration for treating Covid-19 patients.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.cnbc.com\/2020\/10\/28\/remdesivir-gileads-revenue-rises-17percent-on-sales-of-coronavirus-treatment-.html\">To read this article:<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(CNBC) Gilead Sciences reported stronger-than-expected third-quarter earnings on Wednesday as sales of its coronavirus treatment remdesivir touted by President Donald Trump drove revenue up by 17% from last year. Gilead\u2019s antiviral drug remdesivir, selling under the brand name Veklury, last [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-76075","post","type-post","status-publish","format-standard","hentry","category-syndicated"],"_links":{"self":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/76075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/comments?post=76075"}],"version-history":[{"count":1,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/76075\/revisions"}],"predecessor-version":[{"id":76076,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/76075\/revisions\/76076"}],"wp:attachment":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/media?parent=76075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/categories?post=76075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/tags?post=76075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}